Trial Profile
A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation; Ocular pain
- Focus Therapeutic Use
- Sponsors InSite Vision; Sun Pharma Global FZE; Sun Pharmaceutical Industries
- 24 Jun 2020 Status changed from active, no longer recruiting to completed.
- 19 Mar 2020 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.
- 13 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Feb 2020.